Company Description: We are pioneering a novel approach by integrating proprietary synthetic biology methods and de novo protein designs with the power of generative AI to automate the discovery process and develop patient-tailored immune-mediated therapies at scale for Chronic and Age-Related diseases (tech-bio platform). Our platform has been validated across different case studies (in vitro, in vivo) including (T-Cell Engagers, CAR-T/NK), completed 2 pilot studies (4LOIs), 1 pilot confirmed with major pharma, part of Merck DSS, TMC for Cancer Therapeutics, Pear VC PFC, J&J with initial investments from some VCs.